Lexeo Therapeutics, Inc.
Key Metrics
- Previous Close
- $2.86
- 52-Week Range
- $2.55 – $10.99
- Market Cap
- $244.23M
- P/E (TTM)
- —
- EPS (TTM)
- -1.13
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.13
- PEG Ratio
- —
- Return on Equity
- -62.39%
- Return on Assets
- -36.71%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 8.69
- Debt/Equity
- 0.03
- Total Debt
- $6.25M
- Free Cash Flow
- $-53.17M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $55.68M
Market Snapshot
About
Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for cardiovascular, central nervous system, and ocular diseases. The company utilizes adeno-associated virus (AAV) delivery platforms to address genetic disorders with significant unmet medical needs. Lexeo focuses on one-time therapeutic interventions that could provide long-term benefits to patients with inherited conditions.